SULFAMETHOXAZOLE AND TRIMETHOPRIM tablet

国: アメリカ合衆国

言語: 英語

ソース: NLM (National Library of Medicine)

有効成分:

SULFAMETHOXAZOLE (UNII: JE42381TNV) (SULFAMETHOXAZOLE - UNII:JE42381TNV), TRIMETHOPRIM (UNII: AN164J8Y0X) (TRIMETHOPRIM - UNII:AN164J8Y0X)

から入手可能:

Denton Pharma, Inc. DBA Northwind Pharmaceuticals

INN（国際名）:

SULFAMETHOXAZOLE

構図:

SULFAMETHOXAZOLE 800 mg

投与経路:

ORAL

処方タイプ:

PRESCRIPTION DRUG

適応症:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibac

製品概要:

Sulfamethoxazole and trimethoprim tablets, USP are supplied as follows: Sulfamethoxazole 800 mg and trimethoprim 160 mg tablets, double strength, white, oval shaped, scored, debossed MP 85 Bottles of 6 NDC 70934-043-06 Bottles of 12 NDC 70934-043-12 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature] DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.

認証ステータス:

Abbreviated New Drug Application

製品の特徴

SULFAMETHOXAZOLE AND TRIMETHOPRIM- SULFAMETHOXAZOLE AND TRIMETHOPRIM
TABLET
DENTON PHARMA, INC. DBA NORTHWIND PHARMACEUTICALS
----------
SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS USP
RX ONLY
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of
sulfamethoxazole and trimethoprim tablets and other antibacterial
drugs, sulfamethoxazole and
trimethoprim tablets should be used only to treat or prevent
infections that are proven or strongly
suspected to be caused by bacteria.
DESCRIPTION
Sulfamethoxazole and trimethoprim is a synthetic antibacterial
combination product available in DS
(double strength) tablets, each containing 800 mg sulfamethoxazole and
160 mg trimethoprim; in tablets,
each containing 400 mg sulfamethoxazole and 80 mg trimethoprim for
oral administration.
Sulfamethoxazole is _N_ -(5-methyl-3-isoxazolyl)sulfanilamide; the
molecular formula is C
H
N
O
S. It is an almost white, odorless, tasteless compound with a
molecular weight of 253.28 and the
following structural formula:
Trimethoprim is 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine; the
molecular formula is C
H
N
O
. It is a white to light yellow, odorless, bitter compound with a
molecular weight of 290.3 and the
following structural formula:
INACTIVE INGREDIENTS: Docusate sodium 85%, sodium benzoate 15%, sodium
starch glycolate,
magnesium stearate and pregelatinized starch.
CLINICAL PHARMACOLOGY
Sulfamethoxazole and trimethoprim is rapidly absorbed following oral
administration. Both
sulfamethoxazole and trimethoprim exist in the blood as unbound,
protein-bound and metabolized forms;
sulfamethoxazole also exists as the conjugated form. Sulfamethoxazole
is metabolized in humans to at
least 5 metabolites: the N
-acetyl-, N
-hydroxy-, 5-methylhydroxy-, N
-acetyl- 5-methylhydroxy-
1
10
11
3
3
14
18
4
3
4
4
4
sulfamethoxazole metabolites, and an N-glucuronide conjugate. The
formulation of N
-hydroxy
metabolite is mediated _via_ CYP2C9.
Trimethoprim is metabolized _in vitro_ to 11 different metabolites, of
which, five